Generic Name and Formulations:
Luliconazole 1%; cream.
Valeant Pharmaceuticals, Inc
Indications for LUZU:
Interdigital tinea pedis, t. cruris, and t. corporis caused by Trichophyton rubrum and Epidermophyton floccosum.
Adults and Children:
Apply to affected area and approximately 1 inch of the immediate surrounding area(s) once daily. T. corporis (≥2yrs): treat for 1 week. T. pedis (≥12yrs): treat for 2 weeks. T. cruris (≥12yrs): treat for 1 week.
Not for ophthalmic, oral, or intravaginal use. Pregnancy. Nursing mothers.
May inhibit CYP2C19 activity.
Application site reactions.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Researchers Identify Novel Potential Biomarkers for Autism
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Triiodothyronine in the Treatment of Bipolar Depression
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer Disease Examined
- Many Teens Who Use Tobacco Don't Self-Identify as Users